Volume 15, Issue 5 (6-2017)                   IJRM 2017, 15(5): 305-310 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jamshidi Makiani M, Minaeian S, Moghaddam S A, Moosavi S A, Moeini Z, Zamani V, et al . Relative frequency of human papillomavirus genotypes and related sociodemographic characteristics in women referred to a general hospital in Tehran, 2014- 2015: A cross-sectional study. IJRM 2017; 15 (5) :305-310
URL: http://ijrm.ir/article-1-822-en.html
Relative frequency of human papillomavirus genotypes and related sociodemographic characteristics in women referred to a general hospital in Tehran, 2014- 2015: A cross-sectional study
Mahin Jamshidi Makiani1 , Sara Minaeian * 2, Soheila Amini Moghaddam3 , Seyed Akbar Moosavi4 , Zahra Moeini5 , Vajihe Zamani6 , Mahnaz Karbalaei Sabbagh7 , Hosein Forghani8
1- Department of Infectious Disease, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
2- Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran , sara.minaeian@gmail.com
3- Department of Gynecology Oncology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
4- Department of Genetic, Tehran University of Medical Sciences, Tehran, Iran
5- Department of Biology, Islamic Azad University of Damghan, Damghan, Iran
6- Department of Obstetrics and Gynecology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
7- Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
8- Department of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract:   (3434 Views)
Background: Human papilloma virus (HPV) is one of the major public healthproblems and the main causes of cervical cancer. The prevalence HPV infection indeveloping countries with low financial resources is high.
Objective: This study aimed to determine the relative frequency of HPV genotypesand its sociodemographic characteristics in women referred to a general hospital inTehran, Iran from 2014-2015.
Materials and Methods: This cross-sectional study was performed in 400 womenwith Pap smear samples, referring to to a general hospital in Tehran, Iran from 2014-2015. The detection of 28 HPV genotypes was performed by using the MultiplexPCR technique. The sociodemographic survey was conducted for each HPV positivewoman.
Results: HPV-positive infection was detected in 155 (38.75%) women aged 17-85years. HPV 16 (19.1%) was the most prevalent type, followed by HPV 39 (12.5%)and HPV 18 (8.9%). The highest rate of HPV infection was observed at the age of36 years (7.7%). The level of education and economic situation of each woman wereshowed most of HPV-positive women had a high school diploma (34.6%) andaverage economic situation (67,9%). 60.9% of these women were a housewife, and67.3% lived in the capital .
Conclusion: Determination of HPV genotype and risk factor related to HPVinfection in each geographical region can lead to the production of effectivevaccines against the HPV virus. It can also be useful for disease management andhigh sensitivity diagnosis of cervical intraepithelial neoplasia.
Keywords: Human papilloma virus, Frequency, Multiplex PCR, Socioeconomic factors.
Full-Text [PDF 404 kb]   (904 Downloads) |   |   Full-Text (HTML)  (343 Views)  
Type of Study: Original Article |
References
1. Minaeian S, Rahbarizadeh F, Zarkesh-Esfahani SH, Ahmadvand D, Broom OJ. Neutralization of human papillomavirus by specific nanobodies against major capsid protein L1. J Microbiol Biotechnol 2012; 22: 721-728. [DOI:10.4014/jmb.1112.12001]
2. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006; 24: S11-S25. [DOI:10.1016/j.vaccine.2006.05.111]
3. De Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27. [DOI:10.1016/j.virol.2004.03.033]
4. Tsakogiannis D, Diamantidou V, Toska E, Kyriakopoulou Z, Dimitriou T, Ruether I, et al. Multiplex PCR assay for the rapid identification of human papillomavirus genotypes 16, 18, 45, 35, 66, 33, 51, 58, and 31 in clinical samples. Arch Virol 2015; 160: 207-214. [DOI:10.1007/s00705-014-2261-6]
5. Moscicki A-B, Schiffman M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24: S42-S51. [DOI:10.1016/j.vaccine.2006.06.018]
6. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Oxford Univ Press; 2008.
7. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16: 1-17. [DOI:10.1128/CMR.16.1.1-17.2003]
8. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Prevent Biomark 2001; 10: 45-52.
9. Orozco-Colín A, Carrillo-García A, Méndez-Tenorio A, Ponce-de-León S, Mohar A, Maldonado-Rodríguez R, et al. Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology. Int J Infect Dis 2010; 14: 1082-1087. [DOI:10.1016/j.ijid.2010.07.007]
10. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-1799. [DOI:10.1086/657321]
11. Khorasanizadeh F, Hassanloo J, Khaksar N, Taheri SM, Marzaban M, Rashidi BH, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women-Analyses of national data and systematic review of the literature. Gynecol Oncol 2013; 128: 277-281. [DOI:10.1016/j.ygyno.2012.11.032]
12. Yousefzadeh A, Mostafavizadeh SM, Jarollahi A, Raeisi M, Garshasbi M, Siavashvahabi Z, et al. Human papillomavirus (HPV) prevalence and types among women attending regular gynecological visit in Tehran, Iran. Clin Lab 2013; 60: 267-273.
13. Graham JE, Mishra A. Global challenges of implementing human papillomavirus vaccines. Int J Equit Health 2011; 10: 27. [DOI:10.1186/1475-9276-10-27]
14. Giorgi Rossi P, Baldacchini F, Ronco G. The possible effects on socio-economic inequalities of introducing HPV testing as primary test in cervical cancer screening programs. Front Oncol 2014; 4: 20. [DOI:10.3389/fonc.2014.00020]
15. Dempsey AF. Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated. Rev Obstet Gynecol 2008; 1: 122.
16. Minaeian S, Rahbarizadeh F, Zarkesh Esfahani SH, Ahmadvand D. Characterization and enzyme-conjugation of a specific anti-l1 nanobody. J Immunoassay Immunochem 2012; 33: 422-434. [DOI:10.1080/15321819.2012.665407]
17. Elnifro EM, Ashshi AM, Cooper RJ, Klapper PE. Multiplex PCR: optimization and application in diagnostic virology. Clin Microbiol Rev 2000; 13: 559-570. [DOI:10.1128/CMR.13.4.559-570.2000]
18. Haghshenas M, Golini-Moghaddam T, Rafiei A, Emadeian O, Shykhpour A, Ashrafi GH. Prevalence and type distribution of high-risk human papillomavirus in patients with cervical cancer: a population-based study. Infect Agents Cancer 2013; 8: 20. [DOI:10.1186/1750-9378-8-20]
19. Romero-Pastrana F. Detection and typing of human papilloma virus by multiplex PCR with type-specific primers. ISRN Microbiol 2012; 2012.
20. Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol 2008; 1: 2.
21. Möbius G. Cytological early detection of cervical carcinoma: possibilities and limitations. Analysis of failures. J Cancer Res Clin Oncol 1993; 119: 513-521. [DOI:10.1007/BF01686460]
22. Bashizadeh-Fakhar H, Ghane M, Faraji R, Ashoorizadeh B. Identifying Human Papilloma Virus (HPV) in Women with Genital Warts by Multiplex–PCR Method. Zahedan J Res Med Sci 2013; 15: 45-48.
23. Clifford G, Gallus S, Herrero R, Munoz N, Snijders P, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991-998. [DOI:10.1016/S0140-6736(05)67069-9]
24. Salehi-Vaziri M, Sadeghi F, Hashemi FS, Haeri H, Bokharaei-Salim F, Monavari SH, et al. Distribution of Human Papillomavirus genotypes in Iranian women according to the severity of the cervical lesion. Iran Red Crescent Med J 2016; 18: e24458. [DOI:10.5812/ircmj.24458]
25. Shafaghi B, Jarollahi A, Yousefzadeh B, Ameri A, Moghadam S, Mostafavi M. Human Papilloma Virus Prevalence and Types among Iranian Women Attending Regular Gynecological visits. Reports of Radiotherapy and Oncology 2013; 1: 73-79.
26. Ghaffari SR, Sabokbar T, Mollahajian H, Dastan J, Ramezanzadeh F, Ensani F, et al. Prevalence of human papillomavirus genotypes in women with normal and abnormal cervical cytology in Iran. Asian Pacific J Cancer Prevent 2006; 7: 529.
27. Malary M, Moosazadeh M, Hamzehgardeshi Z, Afshari M, Moghaddasifar I, Afsharimoghaddam A. The prevalence of cervical human papillomavirus infection and the most at-risk genotypes among Iranian healthy women: A systematic review and meta-analysis. Int J Prevent Med 2016; 7: 70. [DOI:10.4103/2008-7802.181756]
28. Allameh T, Moghim S, Farahbod F. Reviewing the Prevalence of Human Papillomavirus (HPV) in married women aged 18-60 years with normal Pap smear referring to gynecology clinics in hospitals affiliated to Isfahan University of Medical Sciences, Iran. J Isfahan Medl School 2012; 29: .
29. Clifford G, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73. [DOI:10.1038/sj.bjc.6600688]
30. Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol Oncol 2006; 103: 12-17. [DOI:10.1016/j.ygyno.2006.07.031]
31. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-819. [DOI:10.1001/jama.297.8.813]
32. Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 2006; 12: 462-472.
33. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1808-1816. [DOI:10.1086/428779]
34. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009; 115: S15-S23. [DOI:10.1016/j.ygyno.2009.09.021]
35. Kim KD, Kim JJ, Kim SM, No JH, Kim YB. Prevalence and determinants of high-risk human papillomavirus infection in women with high socioeconomic status in Seoul, Republic of Korea. Asian Pacific J Cancer Prevent 2012; 13: 269-273. [DOI:10.7314/APJCP.2012.13.1.269]
36. Bahrami N, Soleimani MA, Chan YH, Ghojazadeh M, Mirmiran P. Menarche age in Iran: A meta-analysis. Iran J Nurs Midwif Res 2014; 19: 444-450.
37. Syrjänen K, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, et al. Age at menarche is not an independent risk factor for high-risk human papillomavirus infections and cervical intraepithelial neoplasia. Int J STD AIDS 2008; 19: 16-25. [DOI:10.1258/ijsa.2007.007042]
38. Winer RL, Feng Q, Hughes JP, O'reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197: 279-282. [DOI:10.1086/524875]
39. Smith E, Johnson S, Ritchie J, Feddersen D, Wang D, Turek L, et al. Persistent HPV infection in postmenopausal age women. Int J Gynecol Obstet 2004; 87: 131-137. [DOI:10.1016/j.ijgo.2004.07.013]
40. Winer RL, Hughes JP, Feng Q, O'reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. New Eng J Med 2006; 354: 2645-2654. [DOI:10.1056/NEJMoa053284]
41. Halimi L, Haghdoost AA, Alizadeh SM. Prevalence of cigarette smoking among Iranian women: a systematic review and meta-analysis. Med J 2013; 27: 132.
42. Kumar R, Rai AK, Das D, Das R, Kumar RS, Sarma A, et al. Alcohol and tobacco increases risk of high risk HPV infection in head and neck cancer patients: Study from North-East Region of India. PloS One 2015; 10: e0140700. [DOI:10.1371/journal.pone.0140700]
43. Dimitrov G, Džikova E, Dimitrov G, Babushku G, Antovska V. The influence of HPV16, smoking and coitarche in the development of cervical dysplasia in the stage where conization is the treatment of choice. Acta Facult Med Naissens 2012; 29: 181-186.
44. Gunnell AS, Tran TN, Torrång A, Dickman PW, Sparén P, Palmgren J, et al. Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol Biomark Preven 2006; 15: 2141-2147. [DOI:10.1158/1055-9965.EPI-06-0399]
45. Rossi PG, Baldacchini F, Ronco G. The possible effects on socio-economic inequalities of introducing HPV testing as primary test in cervical cancer screening programs. Frontiers Oncol 2014; 4.
46. Benard VB, Johnson CJ, Thompson TD, Roland KB, Lai SM, Cokkinides V, et al. Examining the association between socioeconomic status and potential human papillomavirus‐associated cancers. Cancer 2008; 113: 2910-2918. [DOI:10.1002/cncr.23742]
47. Catarino R, Vassilakos P, Tebeu P-M, Schäfer S, Bongoe A, Petignat P. Risk factors associated with human papillomavirus prevalence and cervical neoplasia among Cameroonian women. Cancer Epidemiol 2016; 40: 60-66. [DOI:10.1016/j.canep.2015.11.008]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb